Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Durvalumab Plus Chemotherapy Improves Survival in Advanced Biliary Tract Cancer

January 18th 2022

Treatment with the PD-L1 inhibitor durvalumab in combination with gemcitabine and cisplatin resulted in significantly improved overall survival vs placebo plus chemotherapy in patients with advanced biliary tract cancer.

FDA Grants Fast Track Designation to CYNK-101 for HER2+ Gastric/GEJ Cancers

January 18th 2022

The FDA has granted a fast track designation to CYNK-101 in combination with standard frontline chemotherapy, trastuzumab, and pembrolizumab for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.

GI Armamentarium Undergoes Changes With New Treatment Mechanisms and Applications

January 12th 2022

Chih-Yi (Andy) Liao, MD, discusses the focus of each presentation at the webinar, which centered on optimizing therapy in advanced pancreatic cancer, the contemporary use of surgery and systemic therapy in NETs, multidisciplinary approaches to hepatocellular carcinoma, and the evolving role of liver transplant and systemic therapy.

Dr. Khushman on Best Practices in the Management of GI Cancers

January 7th 2022

Moh’d Khushman, MD, discusses best practices in the management of gastrointestinal cancers.

Aggarwal Shines a Light on Precision Medicine in Lung, Breast, Ovarian, and GI Cancers

January 6th 2022

Molecular testing is an established and essential precursor to treatment for patients with non–small cell lung cancer based on the volume of actionable targets, such as EGFR and KRAS G12C mutations, as well as PD-L1 status.

Dr. Manne on the Need for Novel Therapies in HCC Without Preserved Liver Function

January 3rd 2022

Ashish Manne, MBBS, discusses the need to develop novel therapies for patients with hepatocellular carcinoma without preserved liver function.

Practice-Changing Data From 2021 Sets Tone for New Year

December 29th 2021

Throughout 2021, investigators of several pivotal trials presented findings that may result in shifting standards for the treatment of patients across tumor types.

Immunotherapy Approvals Overcome Years of Stagnation in GI Cancers

December 28th 2021

Syma Iqbal, MD, shares the main highlights from an IPC meeting, which centered on the evolving landscapes and importance of implementing best practices for patients with hepatobiliary cancers, locally advanced and advanced pancreatic cancer, advanced gastric/gastroesophageal junction cancer, and metastatic colorectal cancer.

Sequencing Strategies May Shift With Emerging Options in GI Malignancies

December 24th 2021

With the rapid uptake of novel therapies, including immunotherapy and targeted therapy, shifts in treatment strategies are anticipated in hepatobiliary cancers, locally advanced and advanced pancreatic cancer, gastric/gastroesophageal junction cancers, and metastatic colorectal cancer.

FDA Approval Sought for EirGenix Trastuzumab Biosimilar for HER2+ Breast and Gastric Cancers

December 21st 2021

A biologics license application has been submitted to the FDA seeking the approval of a proposed biosimilar for trastuzumab, a monoclonal antibody that is utilized in the treatment of patients with HER2-positive breast cancer and metastatic gastric cancers.

Hochster Underscores Headway Made in Gastric/GEJ Cancers

December 16th 2021

Dr. Hochster provides insight into the current gastric/GEJ landscape, spotlighting molecular testing approaches, the roles of chemoimmunotherapy combinations, ongoing research with biomarkers of response, and optimal treatment sequencing for patients with HER2-positive disease.

Dr. Vaishampayan on the Utility of FGFR Inhibitors in Urothelial Cancer

December 8th 2021

Ulka Nitin Vaishampayan, MBBS, discusses the utility of FGFR inhibitors in ​metastatic urothelial cancer.

ESMO 2021 Updates in Gastric Cancer and Colorectal Cancer

December 6th 2021

Sam Klempner, MD; Daniel H. Ahn, DO; Nataliya V. Uboha, MD, PhD; and Manish A. Shah, MD, FASCO, review recent updates in second-line gastric cancer, CAR T-cell therapy in solid tumors, and colorectal cancer presented at ESMO 2021.

Future Directions for HCC Management

December 1st 2021

Drs Josep Llovet, Stephen L. Chan, and Andrea Casadei Gardini discuss the future treatment landscape for HCC.

Management of Advanced HCC Associated With NASH

December 1st 2021

Stephen L. Chan, MD, leads the discussion on the prevalence and management of advanced HCC in patients with NASH.

Treatment Options for Advanced HCC With Underlying NASH

December 1st 2021

A panel of experts in gastroenterology review the case of a 65-year-old man with advanced HCC associated with NASH and comment on treatment with TKIs and immunotherapy.

Investigators Still Working to Understand the Causes of Rare Gastric Cancer

December 1st 2021

Investigators have known about hereditary diffuse gastric cancer syndrome for decades, but only identified its molecular causes in the 1990s, said gastrointestinal oncologist Bryson Katona, MD, PhD.

Frontline Pembrolizumab Plus Chemotherapy Approved in Japan for Esophageal Carcinoma

November 30th 2021

The Japan Pharmaceuticals and Medical Devices Agency has approved the PD-1 inhibitor pembrolizumab for frontline use in combination with 5-fluorouracil plus cisplatin chemotherapy in patients with radically unresectable, advanced, or recurrent esophageal carcinoma.

Role of Genomic Testing in mCRC

November 30th 2021

Experts in gastrointestinal cancers review the role of genomic testing in metastatic colorectal cancer and its impact on informing treatment decisions.

Overview of Colorectal Cancer

November 30th 2021

Tanios S. Bekaii-Saab, MD, Gerald Prager, MD, and Chiara Cremolini, MD, PhD, provide insight on the treatment landscape and international screening guidelines of colorectal cancer.